A recent study aimed to evaluate patients’ and nurses’ preferences for the autoinjector for a biosimilar adalimumab marketed as Imraldi in the European Union versus autoinjectors of reference adalimumab or reference etanercept.
Medication nonadherence is common in patients receiving biologic anti—tumor necrosis factor (anti-TNF) treatment and is associated with increased disease activity and disease flares, loss of responsiveness to anti-TNF treatment, poorer quality of life, increased healthcare expenditures, and higher disability in patients. Patients with inflammatory conditions and nurses tend to prefer autoinjectors over prefilled syringes, studies have shown, as autoinjectors may be easier to use, more convenient, and less painful than syringes, which can increase adherence.
A recent study aimed to evaluate patients’ and nurses’ preferences for the autoinjector for the biosimilar adalimumab marketed as Imraldi in the European Union versus autoinjectors of reference adalimumab (Humira) or reference etanercept (Enbrel). The authors said head-to-head comparative studies of the biosimilar's autoinjector versus other autoinjectors of biologic anti-TNF therapies are needed to determine whether the biosimilar's autoinjector attributes improve patient and nurse satisfaction. Improving satisfaction could improve adherence as well, which could increase treatment efficacy and reduce costs.
The biosimilar's device features a nonslip surface and a rounded 4-sided shape, clicks audibly to indicate the start and end of dose administration, has a button-free initiation mechanism, has small needle size, and has a large medication-viewing window with an indicator to confirm that the injection is complete.
There were 2 face-to-face surveys of patients as well as nurses experienced with educating patients. The first study compared the autoinjectors of biosimilar and reference adalimumab, and the second compared the autoinjectors of biosimilar adalimumab and reference etanercept.
Only nurses with sufficient experience administering autoinjector devices and training patients how to use them were eligible to take part. Patients were aged 18 to 65 years and had a diagnosis of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, or Crohn disease. They were required to have been injecting the reference adalimumab themselves via an autoinjector for at  least 3 months; prior experience with the biosimilar or etanercept autoinjectors was not required for enrollment.
Overall, 101 nurses (United Kingdom, n = 50; Germany, n = 51) and 151 patients (United Kingdom, n = 90; Germany, n = 61) participated in the studies.
In the first study, 85% of nurses and 78% of patients preferred the biosimilar's autoinjector over the reference adalimumab autoinjector (P  < .001). In the second study, 86% of nurses and 79% of patients preferred the biosimilar's autoinjector over the etanercept autoinjector (P  < .001). Survey respondents preferred the biosimilar's autoinjector for its ergonomics, ease of use, ease of grip, and button-free initiation mechanism.
Most nurses indicated they would recommend the biosimilar's autoinjector over the reference adalimumab or etanercept autoinjectors, and most patients indicated they would choose the biosimilar's autoinjector over either reference autoinjector to continue treatment. For patients, results were consistent irrespective of age, country, or condition; for nurses, results were consistent regardless of country, specialty, or prior familiarity with the etanercept autoinjector.
There were 2 main limitations to the survey:
The study was funded by Biogen, part of Samsung Bioepis, maker of Imraldi, and 2 of the 3 authors are employed by the company.
Reference
Fenwick S, Thakur K, Munro D. Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European survey. [published online February 21, 2019]. Rheumatol Ther. doi: 10.1007/s40744-019-0144-8.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.